{"url_path":"/sec/tela/8-k/2026-06-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-072931-index.html","accession_number":"0001104659-26-072931","cik":"0001561921","ticker":"TELA","issuer_name":"TELA Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1561921/0001104659-26-072931-index.html","primary_entity_key":"0001561921","primary_entity_name":"TELA Bio, Inc."},"word_count":202,"has_tables":true,"body_markdown":"**Item 5.02**\n**Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 9, 2026, at the 2026 Annual Meeting of Stockholders (the\n“**Annual Meeting**”) of TELA Bio, Inc. (the “**Company**”), the Company’s stockholders\napproved the amendment (the “**Plan Amendment**”) to the Company’s Amended and Restated 2019 Equity Incentive\nPlan, as amended (the “**A&R 2019 Plan**”), to, among other things, increase the authorized shares issuable\nunder the A&R 2019 Plan by 3,500,000 shares. The Plan Amendment previously had been approved, subject to stockholder approval, by\nthe Board of Directors of the Company (the “**Board**”). The Plan Amendment became effective immediately upon stockholder\napproval at the Annual Meeting.\n\n \n\nA description of the material terms of the Plan Amendment is contained\nin the Company’s Definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30,\n2026 (the “**Proxy Statement**”). The foregoing description of the Plan Amendment and the summary contained in the\nProxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Plan Amendment,\nwhich is filed as Exhibit 10.1 to this Current Report on Form 8-K."}